Purple Biotech PPBT 深 滬
等待開盤 02-04 09:30:00 美东时间
0.5891
-0.017
-2.79%
華盛通- 最 高0.628
- 今 開0.628
- 成交量 4.68万股
- 最 低 0.567
- 昨 收 0.606
- 總市值 531.98万
- 52周最高 3.4755
- 市盈率 靜 --
- 換手率 0.52%
- 52周最低 0.5326
- 委 比 -54.36%
- 總股本 903.04万
- 歷史最高 1390.00
- 量 比 0.43
- 振 幅 10.07%
- 歷史最低 0.5326
- 每 手 1
- 風險率 0.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
Purple Biotech Ltd. announced successful completion of a non-human primates toxicology study of IM1240, a tri-specific antibody targeting 5T4, demonstrating improved safety with reduced immune-related toxicity and cytokine release at doses up to 300-fold higher than a non-capped comparator. IM1240 also showed a favorable pharmacokinetic profile with increased systemic exposure and prolonged half-life. The company plans to advance IM1240 toward fi...
01-07 13:00
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
Purple Biotech Ltd. reported positive preclinical data for their CAPTN-3 tri-specific antibody platform at the ESMO IO Congress 2025. The platform demonstrated strong anti-tumor activity across two antibodies, IM1240 and IM1305, targeting different tumor antigens. IM1240 showed efficacy in PD-1-resistant models, while IM1305 validated the platform's adaptability. The NKG2A arm contributed significantly to immune activation, supported by transcrip...
2025-12-11 12:00
Purple Biotech To Present New Preclinical Data From CAPTN-3 Platform Of Conditionally Activated Tri-Specific Antibodies At ESMO-IO 2025 Annual Congress
New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple
2025-12-04 20:10
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 12.1% to $8.18 during Mond...
2025-11-25 05:05
Purple Biotech Unveils November 2025 Corporate Presentation Highlighting Oncology Advances
The latest update is out from Purple Biotech ( ($PPBT) ). On November 19, 2025,...
2025-11-20 06:27
Purple Biotech Q3 EPADS $(0.29) Misses $(0.26) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.26) by 11.54 percent. This is a 25.64 percent increase over losses of $(0.39) per share from
2025-11-14 21:25
Purple Biotech GAAP EPADS of -$0.86
Purple Biotech press release (PPBT): Q3 GAAP EPADS of -$0.86. Cash position of $10.5 million as of September 30, 2025, with an anticipated cash runway into the first half of 2027, supporting the devel...
2025-11-14 21:12
Purple Biotech shares are trading higher after the company achieved a commercially viable yield for IM1240, positioning the program for future development.
Purple Biotech shares are trading higher after the company achieved a commercia...
2025-10-29 19:34
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
Purple Biotech achieved a manufacturing milestone for its tri-specific antibody IM1240, targeting the tumor-associated antigen 5T4, CD3 on T cells, and NKG2A on NK/T cells. This milestone validates the scalability of their CAPTN-3 platform and positions IM1240 for potential clinical trials with IND submission planned for 2026. The公司 developed a high-efficiency, pure manufacturing process designed to minimize off-tumor immune activation. Their CAP...
2025-10-29 11:33
Purple Biotech announces receipt of Nasdaq minimum bid price notification
Purple Biotech Ltd (NASDAQ:PPBT) said on Monday it received a notice from Nasdaq that its American Depositary Shares (ADSs) have been below the $1 minimum bid price required for continued listing for ...
2025-10-21 04:08
